Skip to Content

'
Amin M. Alousi, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Amin M. Alousi graduated from Wayne State University Medical School in 1997. He completed residencies in Internal Medicine and Pediatrics at Wayne State University (1997–2001), served as Chief Medical Resident at Detroit Receiving Hospital (2001-2002), and fellowships in Adult Hematology and Oncology at Karmanos Cancer Institute (2002-2005). In 2005 he came to M. D. Anderson Cancer Center to receive specialty training in Hematopoietic Stem Cell Transplantation (BMT). He was appointed Assistant Professor of Medicine at M. D. Anderson Cancer Center in 2005 where he specializes in the treatment of various hematologic malignancies. His primary field of research is in the prevention and treatment of graft versus host disease for which he is the principle investigator on numerous clinical trials. He also helps to establish guidelines at M. D. Anderson Cancer Center and nationally for “survivorship” needs for patients following allogeneic transplantation. He has published several papers and book chapters related to hematology, oncology and graft versus host disease; and serves as reviewer for various journals. He is board certified in Internal Medicine, Pediatrics, Adult Hematology and Adult Oncology.

Education & Training

Degree-Granting Education

1997 Wayne State University School of Medicine, Detroit, MI, MD, Medicine

Professional Memberships

American Society of Blood and Marrow Transplantation
Member, 2005-present
American Society of Clinical Oncology
Member, 2005-present
American Society of Hematology
Member, 2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood 114(3):511-7, 7/2009. e-Pub 5/2009. PMCID: PMC2713466.
2. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 9/2008. e-Pub 6/2008. PMID: 18564354.
3. Alousi A, de Lima M. Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Clin Adv Hematol Oncol 5(7)(7):560-70, 7/2007. PMID: 17679930.
4. Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, LoRusso PM. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs 25(2):147-54, 4/2007. PMID: 17103044.

Abstracts
1. Alousi A, Weisdorf DJ, Logan BR, Bolanos-Meade J, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, Horowitz MM, Levine JE. BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD). Blood 112(11) (#55), 11/2008.
2. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin PW, Pro B, Wang M, Rodriguez A, Hagemeister FB, Macapinlac HA, Podoloff DA, Champlin RE, and Khouri IF. Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Blood 110:11:191a (#620), 11/2007.
3. Alousi AM, Saliba RM, Okoroji GJ, Hosing C, Samuels BI, Champlin RE, Khouri IF. The Influence of PET/Gallium (PET/Gal) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-Cell Lymphoma (LBCL) Receiving Autologous Stem Cell Transplants (ASCT). Blood 108 (#3058), 11/2006.
4. Alousi A, Saliba RM, Okoroji G, Hosing C, Samuels BI, Champlin RE, Khouri IF. The Influence of PET/Gallium (P/G) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-cell Lymphoma Receiving Autologous Stem Cell Transplant (ASCT). Journal of Clinical Oncology 24 (#6518), 6/2006.
5. Alousi A, Parchment R, Bionpally R, Gadgeel S, Weigand R, McCormick J, LoRusso P. Karmanos Cancer Institute/Wayne State University, Detroit, MI. Phase 1 Clinical Trial of XK469 in patients with chemo-refractory solid tumors. Journal of Clinical Oncology 22 (#2020), 7/2004.
6. Alousi A, Klein J, Hamm C, Dansey R, Abella E, Zonder J, Dudley A, Baynes R. Myelo-ablative Conditioning with Busulphan, Cyclophosphamide and Cytarabine for AML and MDS Followed by Allogeneic Transplantation. Blood 98 (#1719), 2001.

Book Chapters
1. Alousi A, de Lima M. Ablative Preparative Regimens. In: Stem Cell Transplantation for Hematologic and Other Disorders, 2nd. Ed(s) R Soiffer. Humana Press, 2008. PMID: 978-1-934115-05-3.
2. de Lima M, Alousi A, Giralt S. Preparative Regimens for Stem Cell Transplantation. In: Hematology: Basic Principals and Practice, 5th. Ed(s) R Hoffman, EJ Benz, SJ Shattil, B Furi, LE Silberstein, P McGlave, H Heslop. Churchill Livingstone, 2008. PMID: 978-0-443-06715-0.

Grant & Contract Support

Title: Blood and Marrow Transplant Clinical Trials Research Network (BMT CTN)
Funding Source: NIH/NHLBI
Role: Collaborator
Principal Investigator: Sergio Giralt
Duration: 10/1/2006 - 9/30/2011
 
Title: Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation.
Funding Source: Genzyme Corporation
Role: Principal Investigator
Duration: 8/25/2006 - 8/31/2011
 
Title: A Phase II Study of Lenalidomide (Revlimid®) As Second Line Therapy In Patients with Chronic Graft-Versus-Host Disease (GVHD)
Funding Source: Celgene
Role: Principal Investigator
Duration: 6/15/2006 - 6/30/2011

Last updated: 11/19/2009